Associazione Malati di Acalasia (AMAF Onlus)

AMAF Monza Onlus was established in March 2017, born from the collective desire of patients to create a supportive community for individuals facing the challenges of autoimmune liver diseases. The organization is headquartered in Monza, Italy, and operates as a non-profit entity.

AMAF Monza Onlus exists to support individuals affected by autoimmune liver diseases, aiming to improve their quality of life and advocate for their rights. The organization seeks to provide comprehensive support and information to patients and their families, facilitating better management of their conditions.

The organization specifically supports patients with autoimmune liver conditions, including Epatite Autoimmune (AIH), Colangite Biliare Primitiva (PBC), Colangite Sclerosante Primitiva (PSC), and Malattie Epatobiliari Correlate ad IgG4.

AMAF Monza Onlus engages in several key activities:

• Advocacy for patient rights and inclusion of diseases in national rare disease lists.
• Educational initiatives to raise awareness among healthcare professionals and the public.
• Direct support programs, including information hotlines and patient consultations.
• Financial support for scientific research and scholarships in the field of autoimmune liver diseases.

The organization provides various forms of assistance to patients and their families, including:

• Information hotlines and consultations to guide patients through their healthcare journey.
• Educational materials and workshops to enhance understanding of autoimmune liver diseases.
• Support in accessing healthcare services and navigating the healthcare system.
• Assistance in obtaining social and healthcare rights, such as disability recognition and related benefits.

AMAF Monza Onlus has successfully supported the establishment of national registries for autoimmune liver diseases, contributing to better data collection and research. The organization has also been instrumental in raising awareness and understanding of these conditions among healthcare providers and the general public.